Women’s health spans the entire lifecycle from childbearing age, pregnancy, perimenopause, to postmenopause. Interwoven with multiple challenges such as hormonal fluctuations, methylation metabolism, chronic low-grade inflammation, and vascular care, single ingredients struggle to meet full-stage demands, making precise ingredient pairing the core direction of women’s nutrition development.
Many people focus on active ingredients for regulating the endocrine system while often overlooking the foundational nutritional support of one-carbon metabolism. Among numerous women’s nutritional ingredients, calcium L-5-methyltetrahydrofolate (active folate calcium) has long broken through the conventional perception of being “only for preconception and pregnancy use.” Without requiring MTHFR enzyme conversion, it directly participates in methylation regulation and homocysteine level modulation, building a solid nutritional foundation for vascular homeostasis, emotional nerve health, and metabolic balance, making it an indispensable baseline active ingredient for women’s full-cycle health maintenance.
Recently, Hygieia’s Femifolin® L-5-Methyltetrahydrofolate Calcium won the Shoushiliao “Innovative Ingredient Certification”. Powered by the self-developed Zymevolver® enzyme engineering platform, it has built a diverse women’s health ingredient matrix covering endocrine regulation, metabolic support, and anti-oxidation/anti-inflammation: Femifolin® L-5-Methyltetrahydrofolate Calcium, S-Equol, and Insopro™ D-Chiro-Inositol, synergizing through synthetic biotechnology to provide high-quality raw material support for women’s full-cycle health solutions.
Folic acid (vitamin B9) participates in critical physiological activities such as human one-carbon metabolism, cell division, and homocysteine regulation. It is an indispensable nutrient for women during preconception and early pregnancy, as well as a core micronutrient supporting women’s full-cycle health.
With the continuous iteration of precision nutrition research, public consumer awareness has shifted significantly, moving market demand from “whether to supplement folic acid” to “which type of folic acid better matches individual metabolic traits.”
Traditional synthetic folic acid requires multiple liver reduction steps (first generating tetrahydrofolate) and methylation metabolism after ingestion to finally produce physiologically active L-5-methyltetrahydrofolate. Large-scale population epidemiological studies have confirmed that MTHFR C677T/A1298C gene polymorphism variations, personal constitution, and long-term dietary habits significantly reduce folate conversion efficiency. Over 78% of the Chinese Han population carries relevant mutation sites, universally facing bottlenecks in folate metabolic conversion.
Multiple 2024 international clinical controlled trials indicate that simply supplementing synthetic folic acid fails to improve folate and homocysteine indicators in genetically variant populations.
In contrast, Hygieia’s Femifolin® L-5-Methyltetrahydrofolate Calcium is the calcium salt form of natural active folate, which can be directly absorbed and utilized by the human body without relying on MTHFR enzyme metabolic conversion.
Embryonic safety tests and reproductive cohort studies have confirmed that this active folate form carries no risk of unmetabolized folic acid accumulation. It can rapidly elevate red blood cell folate levels in mutation populations and steadily downregulate homocysteine, making it suitable for long-term supplementation by preconception and pregnant women, perfectly matching current personalized precision nutrition R&D demands and establishing differentiated core scientific advantages.
The Zymevolver® platform is an integrated R&D and manufacturing base built by Hygieia deeply cultivating the field of synthetic biology: through three core modules—high-throughput enzyme screening, site-directed mutagenesis modification, and intelligent fermentation process regulation—it directionally optimizes catalytic enzyme activity and specificity, substantially enhancing target product conversion rates.
The entire technology system holds complete independent intellectual property rights, with flexible process scale-up capabilities, seamlessly connecting small-scale R&D to ton-scale mass production lines to ensure long-term stable supply for domestic and international clients.
Relying on its proprietary Zymevolver® enzyme engineering evolution platform, Hygieia prepares Femifolin® L-5-Methyltetrahydrofolate Calcium using green bioconversion technology, continuously optimizing purity, impurity control, finished product stability, and mass production consistency.
In addition to molecular technology innovation, the company features comprehensive supporting services, adaptable to tablets, soft capsules, solid beverages, special dietary powders, and other dosage forms, providing full sets of technical data on toxicological safety, stability, and efficacy validation to help downstream brands shorten R&D cycles and achieve stable mass supply.
The product can cover formula development across multiple women’s nutrition tracks:
1. Preconception & Pregnancy Nutrition: Provides directly usable high-activity folate raw materials to improve eugenics-related nutritional formula systems;
2. Folate Metabolism Susceptible Populations: Adapts to individuals with insufficient MTHFR enzyme metabolic capacity, empowering differentiated terminal products with personalized nutritional positioning;
3. Cardiovascular Health: Helps lower homocysteine, protects vascular endothelium, and builds women’s vascular care formulas;
4. Emotional Health Support: Supplies methyl donors, maintains neurotransmitter metabolism, and creates mood-soothing nutrition formulas.
1. Shaping Technical Differentiation Labels to Strengthen Industry Recognition
The current folate ingredient track suffers from severe homogeneity, and third-party professional certification serves as core endorsement distinguishing products’ hard strengths. This award corroborates Hygieia’s innovation capacity across multiple dimensions including craftsmanship, scientific mechanism, and commercial prospects, significantly enhancing the exposure and recognition of Femifolin® L-5-Methyltetrahydrofolate Calcium in the functional food industry while highlighting the technical advantages of domestic bio-manufacturing raw materials.
2. Simplifying Downstream Brand Selection Processes to Enhance R&D Docking Efficiency
When screening ingredients, brand owners heavily value complete technical files, stable quality control, continuous supply, and formulation landing support. This product helps brand owners quickly identify raw material innovation highlights during the initial project screening stage and shorten research cycles; final formula landing still requires comprehensive evaluation combining testing data, stability tests, and compliance documents.
3. Improving Women’s Nutrition Ingredient Matrix to Output Integrated Compound Solutions
This award further consolidates Hygieia’s women’s health ingredient layout. Femifolin® L-5-Methyltetrahydrofolate Calcium can be flexibly paired with proprietary characteristic ingredients such as Insopro™ D-Chiro-Inositol and S-Equol, helping brands build subdivided differentiated products like preconception conditioning and daily women’s care; all compound solutions are premised on efficacy evidence, dosage standards, and raw material compatibility testing during R&D.
4. Promoting Domestic Raw Material Upgrading: Moving from Basic Supply to Value Services
High-end nutritional ingredients compete on technological accumulation, stable mass production, compliance support, and comprehensive client services. Relying on this certification, Hygieia no longer limits itself to single ingredient supply, extending forward into value-added services such as formula R&D, technical synergy, and compliance guidance, providing domestic and international brands with more comprehensive and reliable deep cooperation schemes to help domestic high-end functional ingredients elevate global competitiveness.
Women’s health is a long-term systematic need spanning adolescence, childbearing years, and menopause, influenced by multiple factors including age, routine, and metabolic genes. Truly valuable ingredient innovation cannot stop at conceptual marketing; it must achieve traceable mechanisms, controllable quality, actionable application, and compliant promotion.
This “Innovative Ingredient Certification” is a brand new starting point. In the future, Hygieia will continue to deeply cultivate women’s health core ingredients such as Femifolin® L-5-Methyltetrahydrofolate Calcium, Insopro™ D-Chiro-Inositol, and S-Equol, continuously iterating production processes, improving human application data, and expanding compound formula systems. Meanwhile, it will join hands with brand manufacturers and research institutions to jointly develop science-backed women’s nutrition solutions that fit market demands.
Connecting R&D, production, and terminal consumption with innovativ
e raw materials, and empowering women at different stages with more scientific and personalized health nutrition choices through rigorous and stable biotechnology.
[2] Yang B, Liu Y, Li Y, et al. Geographical Distribution of MTHFR C677T, A1298C and MTRR A66G Gene Polymorphisms in Chinese Han Adults[J/OL]. PLOS ONE,2013,8(3):e57917.
[3] Huang X, Bao H H, Ding C C, et al. Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial (PFAT-Hcy)[J]. European Journal of Nutrition, 2024,63(5):1513-1528.
[4] Lian Z L, Wu Z B, Gu R H, et al. Evaluation of Cardiovascular Toxicity of Folic Acid and 6S-5-Methyltetrahydrofolate-Calcium in Early Embryonic Development[J]. Cells, 2022,11(24):3946.
[5] Servy E J, Fanchin R, Berthaut I, et al. 5-MTHF vs folic acid: a key to pregnancy outcome: a case series[J]. Journal of Assisted Reproduction and Genetics, 2018,35(9):1621-1627.
Hygieia conducts semi-rational design through its proprietary Zymevolver® strain construction technology and enzyme engineering evolution platform, developing next-generation precise and efficient anti-aging molecules. It has constructed a product matrix centered on cellular health and built an R&D and production complex spanning nearly ten thousand square meters, which includes 1,500 square meters of professional R&D and pilot-scale platforms, as well as 8,000 square meters of GMP-compliant production workshops.
The team has established a sound three-tier security assurance system based on toxicological evaluation, animal experiments, and human clinical trials, strictly validating product safety and efficacy across comprehensive multi-stages.
Hygieia has won 10+ invention patents, successively becoming the drafting unit for NMN group standards, L-Ergothioneine group standards, and Alpha-Ketoglutarate group standards. It has obtained international system certifications such as FSSC 22000, HALAL, and KOSHER, and has been evaluated as a Specialized, Refined, Unique and New (SRUN) enterprise, National High-Tech Enterprise, Science and Technology Small and Medium-Sized Enterprise, Innovative Small and Medium-Sized Enterprise, and Synthetic Biology Enterprise, while applying for national-level “Little Giant” status.
